WOODBRIDGE, Conn., January 31 — Bruker Corporation is pleased to sponsor a series of complementary seminars on the Advantages of Multiple Modalities, Image Fusion and Data Analysis in Preclinical Small Animal Imaging that will be held in six cities in the NorthEast and in Texas in March.
March 11 – Princeton, NJ - http://bruker-preclinical.com/princeton
March 12 – New York, City, NY - http://bruker-preclinical.com/newyork
March 14 – Boston, MA - http://bruker-preclinical.com/boston
March 25 – Houston, TX - http://www.bruker-preclinical.com/houston/
March 27 – Dallas, TX - http://www.bruker-preclinical.com/dallas/
March 28 – San Antonio, TX - http://www.bruker-preclinical.com/sanantonio/
Cutting edge non-invasive multimodal imaging technologies and strategies are indispensable in preclinical small animal research. With the introduction of advanced multimodal imaging platforms, novel probes, and animal management systems researchers are now able to combine data sets across imaging technologies easier and faster than ever before. Today, using a broad range of imaging modalities including Optical, X-ray, PET/SPECT and MR to characterize diseases in small animal models has become standard practice. This enables better quantification and understanding of the mechanisms of disease progression at the tissue and cellular level, and ultimately, advances the discovery and development of new biomarkers, drugs, and therapeutics.
In this half-day seminar we will explore the work of various independent research scientists from locations including Yale School of Medicine, Thomas Jefferson University, Beth Israel Deaconess Medical Center, New York University School of Medicine, Emory University, Baylor College of Medicine, the University of Texas at Austin, the University of Texas MD Anderson Cancer Center, and the University of Notre Dame (not all speakers will be at all seminars). They will discuss their strategies, methods and results of using diverse imaging modalities, fusion techniques, and data analysis tools to study biodistribution and efficacy of therapeutic candidates, new probe development and validation, and mechanisms of oxidative damage. The imaging modalities presented will be a combination of Optical (including luminescence, fluorescence, and radioisotopic), X-ray and CT, nuclear (PET/SPECT), and magnetic resonance (MR).
In addition, Bruker scientists will present recent advances in new products for small animal imaging including innovative approaches to PET and SPECT detection technology; a unique, compact cryogen-free permanent magnet system for MRI; a next generation multimodal Optical and X-ray imaging platform; and an animal transport for fusing images across different modalities.
For more information and to register for any of these seminars, please call Bruker BioSpin at 203-786-5610 or visit any of the seminar sites listed above.
Bruker Corporation, a global multi-billion dollar company with over 6,200 employees worldwide, is a technology and market leader in scientific and analytical instrumentation including magnetic resonance imaging (MRI), magnetic particle imaging (MPI) and X-ray micro computer tomography (micro CT) and more. With the addition of high resolution In-Vivo Optical/X-ray and Albira PET, SPECT and CT systems, the Bruker preclinical imaging portfolio is now unparalleled in the market, offering you the most diversified choice of imaging modalities for small animal preclinical research. For more information on Bruker, visit www.bruker.com or call 1-877-747-4357, express code 7. Outside of the United States, call 1-203-786-5657.